Sarah Haessler1,2, Tara Lagu2,3,4, Peter K Lindenauer2,3,4, Daniel J Skiest5,2, Aruna Priya4, Penelope S Pekow4,6, Marya D Zilberberg7, Thomas L Higgins2,3,8, Michael B Rothberg9. 1. Division of Infectious Diseases, Baystate Medical Center, Springfield, Massachusetts, USA. Sarah.Haessler@baystatehealth.org. 2. Tufts University School of Medicine, Boston, Massachusetts, USA. 3. Division of General Medicine, Baystate Medical Center, Springfield, Massachusetts, USA. 4. Center for Quality of Care Research, Baystate Medical Center, Springfield, Massachusetts, USA. 5. Division of Infectious Diseases, Baystate Medical Center, Springfield, Massachusetts, USA. 6. School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, USA. 7. EviMed Research Group, LLC, Goshen, Massachusetts, USA. 8. Division of Pulmonary and Critical Care, Baystate Medical Center, Springfield, Massachusetts, USA. 9. Department of Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: The American Thoracic Society and Infectious Diseases Society of America guidelines for management of healthcare-associated pneumonia (HCAP), first published in 2005, have been controversial regarding the selection of empiric broad-spectrum antibiotics, whether the criteria for HCAP predicts the likelihood of infection with multidrug resistant organisms, and whether HCAP patients have improved outcomes when treated with empiric broad-spectrum antibiotics. METHODS: A retrospective cohort study at 488 US hospitals from July 2007 to November 2011. Patients who met criteria for HCAP were included. Guideline-concordant antibiotics were assessed based on guideline recommendations. We assessed changes in hospital rates of concordant antibiotic use over time and their correlation with outcomes. RESULTS: Among 149,963 patients with HCAP, 19.6% received fully guideline-concordant antibiotics, 21.7% received partially concordant antibiotics, and 58.9% received discordant antibiotics. Guideline concordance increased over time. Rates of fully or partially concordant antibiotics varied across hospitals (median 36.4%; interquartile range 25.8%-49.1%). Among patients who received discordant antibiotics, 81.5% were treated according to community-acquired pneumonia (CAP) guidelines. On average, the rate of guideline concordance increased by 2.2% per 6-month interval, while hospital level rates of mortality, excess length of stay, and progression to respiratory failure did not change. CONCLUSIONS: In this large, nationally representative cohort, only 1 in 5 patients with risk factors for HCAP received treatment that was fully in accordance with guidelines, and many received CAP therapy instead. At the hospital level, increases in the use of concordant antibiotics were not associated with declines in mortality, excess length of stay, or progression to respiratory failure.
BACKGROUND: The American Thoracic Society and Infectious Diseases Society of America guidelines for management of healthcare-associated pneumonia (HCAP), first published in 2005, have been controversial regarding the selection of empiric broad-spectrum antibiotics, whether the criteria for HCAP predicts the likelihood of infection with multidrug resistant organisms, and whether HCAPpatients have improved outcomes when treated with empiric broad-spectrum antibiotics. METHODS: A retrospective cohort study at 488 US hospitals from July 2007 to November 2011. Patients who met criteria for HCAP were included. Guideline-concordant antibiotics were assessed based on guideline recommendations. We assessed changes in hospital rates of concordant antibiotic use over time and their correlation with outcomes. RESULTS: Among 149,963 patients with HCAP, 19.6% received fully guideline-concordant antibiotics, 21.7% received partially concordant antibiotics, and 58.9% received discordant antibiotics. Guideline concordance increased over time. Rates of fully or partially concordant antibiotics varied across hospitals (median 36.4%; interquartile range 25.8%-49.1%). Among patients who received discordant antibiotics, 81.5% were treated according to community-acquired pneumonia (CAP) guidelines. On average, the rate of guideline concordance increased by 2.2% per 6-month interval, while hospital level rates of mortality, excess length of stay, and progression to respiratory failure did not change. CONCLUSIONS: In this large, nationally representative cohort, only 1 in 5 patients with risk factors for HCAP received treatment that was fully in accordance with guidelines, and many received CAP therapy instead. At the hospital level, increases in the use of concordant antibiotics were not associated with declines in mortality, excess length of stay, or progression to respiratory failure.
Authors: Andrew F Shorr; Marya D Zilberberg; Richard Reichley; Jason Kan; Alex Hoban; Justin Hoffman; Scott T Micek; Marin H Kollef Journal: Clin Infect Dis Date: 2011-11-21 Impact factor: 9.079
Authors: Michael B Rothberg; Marya D Zilberberg; Penelope S Pekow; Aruna Priya; Sarah Haessler; Raquel Belforti; Daniel Skiest; Tara Lagu; Thomas L Higgins; Peter K Lindenauer Journal: J Antimicrob Chemother Date: 2015-01-03 Impact factor: 5.790
Authors: R T Attridge; C R Frei; M I Restrepo; K A Lawson; L Ryan; M J V Pugh; A Anzueto; E M Mortensen Journal: Eur Respir J Date: 2011-03-24 Impact factor: 16.671
Authors: S R Tunis; R S Hayward; M C Wilson; H R Rubin; E B Bass; M Johnston; E P Steinberg Journal: Ann Intern Med Date: 1994-06-01 Impact factor: 25.391
Authors: Brandon J Webb; Eddie Stenehjem; Kristin Dascomb; Mark Metersky; Holenarasipur R Vikram; Nathan C Dean Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Jennifer J Schimmel; Sarah Haessler; Peter Imrey; Peter K Lindenauer; Sandra S Richter; Pei-Chun Yu; Michael B Rothberg Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079